Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Net Income: 2019-2025

Historic Net Income for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$112.7 million.

  • Beam Therapeutics' Net Income fell 16.61% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$421.8 million, marking a year-over-year decrease of 191.13%. This contributed to the annual value of -$376.8 million for FY2024, which is 184.25% down from last year.
  • Beam Therapeutics' Net Income amounted to -$112.7 million in Q3 2025, which was down 3.16% from -$109.3 million recorded in Q2 2025.
  • Beam Therapeutics' Net Income's 5-year high stood at $142.8 million during Q4 2023, with a 5-year trough of -$200.4 million in Q1 2021.
  • Over the past 3 years, Beam Therapeutics' median Net Income value was -$96.5 million (recorded in 2023), while the average stood at -$77.1 million.
  • Its Net Income has fluctuated over the past 5 years, first slumped by 621.93% in 2021, then spiked by 472.27% in 2023.
  • Over the past 5 years, Beam Therapeutics' Net Income (Quarterly) stood at -$64.7 million in 2021, then soared by 40.73% to -$38.3 million in 2022, then soared by 472.27% to $142.8 million in 2023, then tumbled by 163.33% to -$90.4 million in 2024, then fell by 16.61% to -$112.7 million in 2025.
  • Its last three reported values are -$112.7 million in Q3 2025, -$109.3 million for Q2 2025, and -$109.4 million during Q1 2025.